Chief Physician, Dr., Doctoral Supervisor, Executive Deputy Director of Plastic and Reconstructive Surgery, Director of the Hemangioma and Vascular Malformation Department, and Director of the Laser Cosmetic Department
Affiliated HospitalShanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital
→
Leading the first Phase II clinical trial of a targeted drug for extracranial arteriovenous malformations in China (the only clinical trial of an AVM-targeted drug approved by the CDE); establishing an internationally leading PROS/FIL disease cohort and sample bank. With 30 years of experience in the field of hemangiomas and vascular malformations, some patients have experienced a lesion volume reduction rate of over 50% after 16 weeks of treatment with the domestically developed innovative drug FCN-159. The team has published 16 series of papers in the field of PIK3CA mutation overgrowth disease spectrum (PROS) and its mechanisms, establishing and reporting an internationally leading PROS/FIL disease cohort and sample bank. Specializes in hemangiomas, vascular malformations, invasive facial lipomas, Cloves syndrome, and neurofibromatosis. The team's research results have been published in authoritative journals such as *Advanced Science* and *The New England Journal of Medicine*, creating a globally recognized "Chinese solution" for diagnosis and treatment.